VitaSpring Biomedical Co. Ltd
VitaSpring Biomedical Co. Ltd., a development-stage biomedical company, engages in the research, development, and commercialization of wellness and healthy lifestyle products. The company focuses on the development of cell-based medical technologies for use in regenerative medicine, preventive health care, beauty, and anti-aging applications. It is also involved in the development of cell medicin… Read more
VitaSpring Biomedical Co. Ltd (VSBC) - Net Assets
Latest net assets as of October 2022: $1.68 Million USD
Based on the latest financial reports, VitaSpring Biomedical Co. Ltd (VSBC) has net assets worth $1.68 Million USD as of October 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.44 Million) and total liabilities ($761.79K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.68 Million |
| % of Total Assets | 68.82% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 834.93 |
VitaSpring Biomedical Co. Ltd - Net Assets Trend (2017–2026)
This chart illustrates how VitaSpring Biomedical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VitaSpring Biomedical Co. Ltd (2017–2026)
The table below shows the annual net assets of VitaSpring Biomedical Co. Ltd from 2017 to 2026.
| Year | Net Assets | Change |
|---|---|---|
| 2026-01-31 | $-2.40 Million | 0.00% |
| 2023-01-31 | $-2.40 Million | -251.91% |
| 2022-01-31 | $1.58 Million | +1537.06% |
| 2021-01-31 | $96.36K | -- |
| 2020-01-31 | $0.00 | -- |
| 2019-01-31 | $-6.92K | -102.37% |
| 2018-01-31 | $-3.42K | -215.70% |
| 2017-01-31 | $2.96K | -- |
Equity Component Analysis
This analysis shows how different components contribute to VitaSpring Biomedical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 338797400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.70K | % |
| Other Components | $970.82K | % |
| Total Equity | $-2.40 Million | 100.00% |
VitaSpring Biomedical Co. Ltd Competitors by Market Cap
The table below lists competitors of VitaSpring Biomedical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EcoGraf Ltd
F:FMK
|
$97.75 Million |
|
199430
KQ:199430
|
$97.77 Million |
|
Bank Artha Graha Internasional
JK:INPC
|
$97.79 Million |
|
DOFRB
IS:DOFRB
|
$97.79 Million |
|
Saturn Metals Ltd
AU:STN
|
$97.73 Million |
|
Graphisoft Park SE Real Estate Development European Company Limited
F:GUV
|
$97.71 Million |
|
NISSHIN GROUP HOLDINGS Company Limited
MU:NFU
|
$97.68 Million |
|
Magyar Bancorp Inc
NASDAQ:MGYR
|
$97.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VitaSpring Biomedical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2026, total equity changed from -2,396,492 to -2,396,492, a change of 0.
- Net loss of 4,164,396 reduced equity.
- Other factors increased equity by 4,164,396.
Equity Change Factors (2023 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.16 Million | -173.77% |
| Other Changes | $4.16 Million | +173.77% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares VitaSpring Biomedical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-01-31 | $0.00 | $1.00 | x |
| 2018-01-31 | $0.00 | $1.00 | x |
| 2019-01-31 | $0.00 | $1.00 | x |
| 2020-01-31 | $0.00 | $1.00 | x |
| 2021-01-31 | $0.00 | $1.00 | x |
| 2022-01-31 | $0.01 | $1.00 | x |
| 2023-01-31 | $-0.01 | $1.00 | x |
| 2026-01-31 | $-0.01 | $1.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VitaSpring Biomedical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-3.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -1.52% | 0.00% | 0.00x | 1.54x | $-340.50 |
| 2018 | 0.00% | -39.27% | 1.26x | 0.00x | $-6.03K |
| 2019 | 0.00% | -130.36% | 1.50x | 0.00x | $-21.70K |
| 2020 | 0.00% | 45.70% | 0.00x | 0.00x | $8.75K |
| 2021 | -109.98% | -171.39% | 1.31x | 0.49x | $-464.06K |
| 2022 | 80.12% | 22.52% | 1.56x | 2.28x | $1.11 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.92 Million |
| 2026 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.92 Million |
Industry Comparison
This section compares VitaSpring Biomedical Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VitaSpring Biomedical Co. Ltd (VSBC) | $1.68 Million | -1.52% | 0.45x | $97.73 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |